This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
3 Jul 2015

Rx-360 Summary of Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products

Recent FDA draft guidance has been developed to address the “lack of clarity” with respect to what chemistry, manufacturing and controls (CMC) information in a marketing application constitutes an established condition or a “regulatory commitment” that, if changed following approval, requires reporting to FDA. The guidance is intended to promote a better understanding of CMC changes that can be made solely under the Pharmaceutical Quality System without the need to report to FDA. Sections of the common technical document (CTD) that typically contains information meeting the definition of an established condition are also highlighted.


To view or download the FDA Guidance, click here

To view or download the Rx-360 Summary of the Guidance, click here

Related News